Production (Stage)
Orchestra BioMed Holdings, Inc.
OBIO
$2.72
-$0.01-0.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 868.00K | 253.00K | 987.00K | 778.00K | 620.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 868.00K | 253.00K | 987.00K | 778.00K | 620.00K |
| Cost of Revenue | 44.00K | 58.00K | 68.00K | 44.00K | 34.00K |
| Gross Profit | 824.00K | 195.00K | 919.00K | 734.00K | 586.00K |
| SG&A Expenses | 6.26M | 5.90M | 5.67M | 6.47M | 5.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.79M | 16.93M | 17.33M | 17.64M | 15.04M |
| Operating Income | -18.92M | -16.68M | -16.34M | -16.86M | -14.42M |
| Income Before Tax | -18.76M | -16.16M | -15.43M | -15.98M | -13.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.76M | -16.16M | -15.43M | -15.98M | -13.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.76M | -16.16M | -15.43M | -15.98M | -13.46M |
| EBIT | -18.92M | -16.68M | -16.34M | -16.86M | -14.42M |
| EBITDA | -18.84M | -16.59M | -16.27M | -16.79M | -14.35M |
| EPS Basic | -0.49 | -0.42 | -0.41 | -0.45 | -0.38 |
| Normalized Basic EPS | -0.31 | -0.27 | -0.26 | -0.28 | -0.23 |
| EPS Diluted | -0.49 | -0.42 | -0.41 | -0.45 | -0.38 |
| Normalized Diluted EPS | -0.31 | -0.27 | -0.26 | -0.28 | -0.23 |
| Average Basic Shares Outstanding | 38.24M | 38.06M | 37.62M | 35.80M | 35.78M |
| Average Diluted Shares Outstanding | 38.24M | 38.06M | 37.62M | 35.80M | 35.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |